Study design and patient demographics of the ULTIMATE phase III trials evaluating Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing multiple sclerosis (RMS)

The requested reference [eb66ac4a587b7649e60f88af04627c7eccb318f0] no longer exists in our database. It has been replaced by the current reference: [2c872b6772fe0e3c99ff9d9f8e220abe9b38efe1]

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2019
This article has no abstract
Epistemonikos ID: 86bde47ce9171f26a707d14c333bfa00fad49e31
First added on: Apr 29, 2026